Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alertwatch, American College of Cardiology, Avellino Labs USA, Clinical Computer Systems, Cybermdx, Exagen, Eyedaptic, Hologic, Htc Vive, Invacare, Invicro, LHC Group, Medicortex Finland, Northwell Labs, Nyxoah, Pavmed, Penumbra, Relyens, Sanmina, Sham, Soliton, Ulab Systems, Vispero.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aguair, Anthem, Avricore, Blue Cross, Ehealth Technologies, Enzo Biochem, Labcorp, Mologic, Silk Road Medical.
A list of biopharma companies and nonprofit entities, including academia, working feverishly to find a vaccine or antiviral treatment to address the rapidly spreading coronavirus, now known as COVID-19, has more than doubled, increasing from about 30 a few weeks ago to 71 as of March 6.
The Senate passed by a vote of 96-1 the spending bill for the outbreak of the new coronavirus (COVID-19), which will be on President Donald Trump’s desk by week’s end. The bill provides $7.8 billion in new funds to tackle the outbreak and another $490 million in existing funds for telehealth, all with the aim of speeding the response to the pathogen.
BEIJING – More and more companies and researchers in China are rolling out artificial intelligence (AI)-based systems that can process hundreds of computed tomography (CT) images in seconds to speed up diagnosis of COVID-19 and assist in its containment.
Keeping you up to date on recent developments in diagnostics, including: Question of COVID-19 contagion window; A paper-based, portable coronavirus test; Finding the next pandemic threat early on; Anatomy study reveals schizophrenia subtypes.
LONDON – The U.K. life sciences sector has stepped into “a new reality” following publication of the government’s negotiating mandate on the future trading relationship with the EU. “Plan A is no longer on the table,” said Steve Bates, chief executive of the Bioindustry Association, who has spent three long years lobbying for a favorable deal for the industry.
In a flurry of catch-up following the coronavirus outbreak in China, a number of biopharma companies have announced development within the last few weeks to address the ever-spreading infection known as COVID-19.
RSS
